Immtech Pharmaceuticals, Inc   Report issue

For profit Phase 2 Phase 3
Founded: New York NY United States (1984)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2001
NCT00802594
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

pafuramidine maleate (5 trials)

sulfamethoxazole (gantanol) (1 trial)

trimethoprim (1 trial)

Drugs in Phase 2 Trials (1)

pentamidine (pentam) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases, Interstitial (Phase 3)

Malaria (Phase 2)

Pneumonia (Phase 3)

Pneumonia, Pneumocystis (Phase 3)

Trypanosomiasis (Phase 2)

Trypanosomiasis, African (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4